Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Related BIIB
AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
John Stumpf And 15 Major CEO Departures In 2016
Related XNPT
Benzinga's M&A Chatter for Monday May 23, 2016
Mid-Afternoon Market Update: KLX Drops On Q1 Results; Resource America Shares Spike Higher

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

Oct 2016JefferiesMaintainsHold
Sep 2016JefferiesDowngradesBuyHold
Aug 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings


Related Articles (BIIB + XNPT)

View Comments and Join the Discussion!